{"filing":{"accession_number":"0001193125-26-330537","cik":"0001623526","ticker":"STOK","company_name":"Stoke Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"stok-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526330537/stok-20260803.htm"},"events":[{"id":23341,"run_id":21103,"accession_number":"0001193125-26-330537","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Stoke Therapeutics issued a press release on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, including Q2 2026 revenue ($9.3M), net loss ($61.6M), R\u0026D expenses ($49.5M), and SG\u0026A expenses ($25.3M), along with year-to-date results. The disclosure is a standard quarterly earnings announcement with detailed financial metrics and business updates, filed under Item 2.02 (Results of Operations and Financial Condition).","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23541,"accession_number":"0001193125-26-330537","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Stoke Therapeutics issued a press release on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, including Q2 2026 revenue ($9.3M), net loss ($61.6M), R\u0026D expenses ($49.5M), and SG\u0026A expenses ($25.3M), along with year-to-date results. The disclosure is a standard quarterly earnings announcement with detailed financial metrics and business updates, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:21:00.456114+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23541,"accession_number":"0001193125-26-330537","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Stoke Therapeutics issued a press release on August 3, 2026 announcing financial results for the quarter ended June 30, 2026, including Q2 2026 revenue ($9.3M), net loss ($61.6M), R\u0026D expenses ($49.5M), and SG\u0026A expenses ($25.3M), along with year-to-date results. The disclosure is a standard quarterly earnings announcement with detailed financial metrics and business updates, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:21:00.456114+00:00","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-08-03"}]}